NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), of the important October 8, 2024 lead plaintiff deadline. SO WHAT: If you purchased Moderna securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT T ...

SYRACUSE, New York, VANCOUVER, British Columbia, and BASEL, Switzerland, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Repair Biotechnologies, a biotechnology company developing first-in-class therapies capable of rapidly regressing atherosclerotic plaque, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust and expansive lipid nanoparticle (LNP) patent portfolio, today announced they have entered into a collaboration and nonexclusive license agreement to combine Repai ...

NEW YORK, Sept. 26, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Moderna, Inc. (NASDAQ: MRNA). Shareholders who purchased shares of MRNA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/moderna-loss-submission-form/?id=105022&from=4 CLASS PERIOD: January 18, 2023 to June 2 ...

NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), of the important October 8, 2024 lead plaintiff deadline. SO WHAT: If you purchased Moderna securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT T ...

NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Moderna, Inc. (NASDAQ: MRNA). Shareholders who purchased shares of MRNA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/moderna-loss-submission-form/?id=104511&from=3 CLASS PERIOD: January 18, 2023 to Ju ...

These innovative companies have the tools to rebound. Pfizer (PFE -0.81%) and Moderna (MRNA -3.42%) were rockstars on the stock market a few years ago. Both companies developed successful coronavirus vaccines, efforts for which they were being handsomely rewarded, financially and on the stock market. However, as the pandemic has subsided, both companies have lost their appeal in the eyes of many investors. Their shares have significantly lagged the market over the past couple of years. Is there any hope tha ...

NEW YORK, Sept. 23, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Moderna, Inc. (NASDAQ: MRNA). Shareholders who purchased shares of MRNA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/moderna-loss-submission-form/?id=104019&from=4 CLASS PERIOD: January 18, 2023 to June 2 ...

There's no hope of it recovering to its prior heights anytime soon. Moderna's (MRNA -2.63%) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a handful of its pipeline programs and terminate a few others. Now, management is cautioning investors that a return to routine profitability may not be in the cards for a couple of years. Is the stock's decline just a blip that's part and parcel with the announcement of less-than-great news, or is there a real risk of a long ...

In my previous article , I argued that Moderna stock was undervalued. Since then, Moderna's stock has rallied to $170 per share (May 24), surpassing my fair valuation level of $157. However, the stock has since suffered a sell-off, and after the R&D day, the stock price was as I am the head of research for the pre-IPO and venture division of the investment bank. Prior to that, I have been working as a global equity research analyst in an investment bank for the past 5 years. My specialization are Biotechnol ...

This strategic play will take time to pay off, but it could keep growth going. On Sept. 16 Novo Nordisk (NVO 0.04%) and Korro Bio (KRRO -1.45%) announced that they'd be starting a new drug-development collaboration worth hundreds of millions of dollars, in an area that most would assume to be Moderna's (MRNA -2.96%) home territory. It's natural for investors to wonder if the competitive landscape in biopharma may have changed in a big way. And it might -- but probably not in the way that some are expecting. ...